Parenchymal versus nonparenchymal target lesion response in clinical trials for metastatic medullary thyroid cancer
- PMID: 20713862
- DOI: 10.1200/JCO.2010.29.9909
Parenchymal versus nonparenchymal target lesion response in clinical trials for metastatic medullary thyroid cancer
Comment on
-
Phase II clinical trial of sorafenib in metastatic medullary thyroid cancer.J Clin Oncol. 2010 May 10;28(14):2323-30. doi: 10.1200/JCO.2009.25.0068. Epub 2010 Apr 5. J Clin Oncol. 2010. PMID: 20368568 Free PMC article. Clinical Trial.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
